Myeloid Leukemias Completed Phase 2 Trials for Mycophenolate mofetil (DB00688)

Back to Myeloid Leukemias

Also known as: Leukemia, Myeloid / Myeloid leukaemia / Myeloid Leukemia / Myeloid leukemia, unspecified, not having achieved remission / Myeloid leukemia, unspecified / Myeloid leukemia (morphologic abnormality) / Myeloid leukemia (disorder) / Leukemia myeloid / Non-lymphoblastic leukaemia NOS / Non-lymphoblastic leukemia NOS / Unspecified myeloid leukaemia / Unspecified myeloid leukemia / Leukaemia myelogenous / Leukemia myelogenous / Myelocytic leukaemia / Myelocytic leukemia / Leukemia granulocytic NOS / Leukaemia granulocytic NOS / Leukaemia granulocytic / Leukemia granulocytic / Leukaemia myeloid / Myeloid leukemia NOS / Myeloid leukaemia NOS

Indication	Status	Phase
DBCOND0042450 (Myeloid Leukemias)	Completed	2

clinicaltrials.gov Identifier	Title	Purpose	Drugs
NCT01392989	Post T-plant Infusion of Allogeneic Cytokine Induced Killer (CIK) Cells as Consolidative Therapy in Myelodysplastic Syndromes/Myeloproliferative Disorders	Treatment	Antithymocyte immunoglobulin (rabbit) (DB00098) Cyclosporine (DB00091) Mycophenolate mofetil (DB00688)
NCT01760655	Reduced-Intensity Conditioning Before Donor Stem Cell Transplant in Treating Patients With High-Risk Hematologic Malignancies	Treatment	1,4-Butanediol (DB01955) Busulfan (DB01008) Cyclophosphamide (DB00531) Fludarabine (DB01073) Mycophenolate mofetil (DB00688) Tacrolimus (DB00864) Therapeutic allogeneic lymphocytes (DB17459)